Brings 20+ years of revenue growth leadership in laboratory testing, clinical diagnostics and global expansion
Biomerica, a global biomedical company leading the way in innovative gastroenterology solutions, announced the appointment of Scott Madel as Chief Commercial Officer.
Scott brings more than two decades of cross-functional expertise in healthcare, diagnostics, commercialization, and payor strategy. Most recently, he served as President of Boston Heart Diagnostics, where he led a successful organizational turnaround, introduced novel cardiovascular testing technologies across diverse payer channels, and significantly boosted revenue through personalized testing solutions.
Health Technology Insights: Pharmacists Expand Clinical Footprint Across U.S. Hospitals
Prior to Boston Heart, he served as CEO of BioHealth Diagnostics and CEO of Genova Diagnostics Europe after initially joining Genova as Vice President of Business Development. During his tenure, he helped grow Genova to over $100 million in annual revenue, launching diagnostics for chronic disease, the development of strategic partnerships across 45 countries, and the profitable turnaround and expansion of an accredited European clinical laboratory.
Scott’s early career experience includes frontline field sales roles at Novartis Pharmaceuticals and Merck, providing him exceptional insight into the full commercial lifecycle. He holds a Bachelor of Science in Medical Microbiology and Immunology from the University of Wisconsin–Madison, studied at King’s College London and is currently completing his MBA from Northeastern University.
Health Technology Insights: Wearable Devices Advances AI Health Monitoring Platform as U.S. HHS Embraces Wearable Tech
In his new role, Scott will expand and accelerate commercialization and revenue growth for inFoods IBS, by focusing on strategic partnerships, developing a robust payer strategy, achieving 3rd party payer reimbursement, and scaling domestic and global provider engagement and brand recognition.
“I’m excited to join Biomerica and champion the growth of inFoods IBS,” said Mr. Madel. “This innovative solution has the potential to substantially improve the quality of life for millions of patients suffering from chronic GI conditions. I look forward to working alongside the team to bring this clinically proven breakthrough technology to practitioners and patients worldwide—delivering better outcomes, improving patient experience, and reducing the cost to treat this chronic condition.”
“Scott’s rich commercial experience, knowledge and deep industry relationships should dramatically increase revenues from inFoods IBS across markets. We’re confident his strategic insights will drive our domestic launch and future international business,” said Zack Irani, CEO of Biomerica.
Health Technology Insights: Healthee Launches Smarter, Simpler, AI-Powered Benefits Platform
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
